Trendlines Group Portfolio Company Seger Surgical Solutions Achieves Breakthrough in Laparoscopic Surgery
Trendlines Portfolio Company Seger Surgical Solutions Achieves Landmark Success in Human Trials of Laparoscopic Bowel Closure Device
Key Highlights
- Seger Surgical Solutions, a Trendlines Group portfolio company, completes three successful first-in-human cases of its SEGER IDEA™ device in El Salvador.
- The SEGER IDEA™ device enables fully intracorporeal (inside the body) bowel closures, eliminating the need for complex hand-sewn sutures or larger incisions associated with traditional methods.
- All procedures demonstrated safety, efficacy, and significant reductions in procedure time.
- This innovation could significantly impact surgical standards and Trendlines’ market position in medtech.
Full Article
The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY), a company specializing in investments in agrifood and medtech innovation, has announced a major milestone for its portfolio company, Seger Surgical Solutions Ltd. Seger’s proprietary SEGER IDEA™ laparoscopic bowel closure device has successfully completed its first-in-human clinical trial, marking a pivotal advancement in the standardization of 100% intracorporeal anastomosis (IA).
The trials, conducted at Zacamil National Hospital in El Salvador, showcased the device’s ability to allow surgeons to align, close, and staple the common enterotomy entirely within the body. This approach eliminates the traditional need for complex hand-sewn sutures or the extracorporeal method, which typically requires larger incisions and external manipulation of the bowel.
Details of the Clinical Trial
- Three first-in-human cases were completed successfully.
- All procedures achieved 100% intracorporeal results, confirming the device’s efficacy and safety.
- Significant reduction in procedure time: Bowel closures were completed in under 2 minutes, compared to the conventional 15–20 minutes required for manual laparoscopic suturing.
- Enhanced patient recovery prospects: The minimally invasive nature of the device (smaller incisions and less tissue handling) is expected to reduce postoperative pain and lower the risk of incisional hernias.
Strategic and Financial Implications for Investors
The successful human trial of the SEGER IDEA™ device is a potentially price-sensitive milestone for Trendlines Group shareholders. The demonstrated safety, efficacy, and efficiency of the device positions Seger — and by extension, Trendlines — at the forefront of innovation in minimally invasive surgical technologies.
The dramatic reduction in procedure time, combined with the promise of better patient outcomes, suggests strong commercial potential and a significant market opportunity. If widely adopted, this device could set a new standard for laparoscopic bowel procedures, making intracorporeal anastomosis more accessible to a broader range of surgeons and hospitals.
Trendlines’ CEO, Haim Brosh, emphasized that this achievement underscores the quality and potential of the company’s portfolio and the impact that its innovation-driven strategy can deliver in healthcare.
Seger’s CEO, Shahar Millis, described the milestone as “making history” and expressed confidence that 100% IA is now a “reachable standard for many,” no longer limited to the most skilled surgeons.
About Trendlines Group
Trendlines Group invests in and develops early-stage agrifood and medtech innovations with operations in Israel and Singapore. The company leverages capital, expertise, and strategic partnerships to transform technologies into impactful businesses, aiming to advance global sustainability and create long-term shareholder value.
Investor Contact Information
Conclusion
The successful human trials of Seger’s SEGER IDEA™ device represent a significant breakthrough for Trendlines Group and its shareholders. The innovation has the potential to disrupt current surgical practices and drive substantial value for the company and its investors, making this a development to watch closely in the coming quarters.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Shareholders and potential investors should conduct their own research and consult with professional advisers before making any investment decisions. The Singapore Exchange Securities Trading Limited (the “Exchange”) assumes no responsibility for the contents of this release.
View Trendlines Historical chart here
